If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
To increase the level of recycling and meet its targets, Tetra Pak engaged in driving recycling activities such as developing collection schemes, launching new recycling technologies, and raising awareness of recycling and sustainability. Used Tetra Pak packages have been recycled as construction material in design projects, with varying results. By 2017, 25% of Tetra Pak cartons were recycled globally. At that time, the company announced that global recycling rates would no longer be one of its main metrics measured in sustainability reports, abandoning its previous target of increasing recycling rates to 40% by 2020, and instead introduced new metrics to measure against, such as public outreach, access to recycling facilities, and recycling capacity. In 2018, Tetra Pak signed an agreement with the environmental services company Veolia "to recycle all the components of used beverage cartons collected within the EU by 2025." Tetra Pak has also partnered with the Certified Renovated Equipment organization to refurbish old equipment so it can be resold as part of a circular economy initiative. In attempts to innovate and to improve the recyclability rate of their Aseptic cartons, one of the main factors is the replacement of the aluminum layer used, which can constitute up to 5% of the package material. In which, exposure to the metal has been suggested as a risk factor for Alzheimer's Disease. The company is currently testing two alternatives as a replacement for aluminum: (1) a fiber-based barrier layer, and (2) a polymer-based barrier.
Grandidier, A. (1899). Guide de l'immigrant à Madagascar (in French). Paris: A Colin et cie. Kurlansky, Mark (1997). Cod: A Biography of the Fish That Changed the World. New York: Walker. ISBN 0-8027-1326-2.
On 22 December 1988, the Brazzaville Protocol was enshrined in the Tripartite Accord, which required the SADF to withdraw from Angola and reduce its troop levels in South West Africa to a token force of 1,500 within twelve weeks. Simultaneously, all Cuban brigades would be withdrawn from the border to an area north of the 15th parallel. At least 3,000 Cuban military personnel would depart Angola by April 1989, with another 25,000 leaving within the next six months. The remaining troops would depart at a date not later than 1 July 1991. An additional condition was that South Africa would cease all support for UNITA, and Angola likewise for PLAN and MK. On 20 December 1988, United Nations Security Council Resolution 626 was passed, creating the United Nations Angola Verification Mission (UNAVEM) to verify the redeployment northwards and subsequent withdrawal of the Cuban forces from Angola. UNAVEM included observers from Western as well as non-aligned and communist nations. In February 1989 the United Nations Transition Assistance Group (UNTAG) was formed to monitor the South West African peace process.
Viral vector vaccines use a safe virus to insert pathogen genes in the body to produce specific antigens, such as surface proteins, to stimulate an immune response. Viruses being researched for use as viral vectors include adenovirus, vaccinia virus, and VSV.
=== Exoenzymes === Exoenzymes are enzymes secreted by microorganisms, such as bacteria and fungi, to function outside their cells. These enzymes are crucial for breaking down large molecules in the environment into smaller ones that the microorganisms can absorb (transport into their cells) and use for growth and energy. Several studies have demonstrated that the activity of extracellular enzymes in aquatic microbial ecology is of algal origin. These exoenzymes released from microalgae include alkaline phosphatases, chitinases, β-d-glucosidases, proteases etc. and can influence the growth of microorganisms, chemical signaling, and biogeochemical cycling in ecosystems. The study of these exoenzymes may help to optimize the nutrient supplement strategy in aquaculture. Nevertheless, only a few of the enzymes were isolated and purified. Selected prominent enzyme classes are highlighted in the cited literature.
Sources: en.wikipedia.org
When El Niño conditions last for many months, extensive ocean warming and the reduction in easterly trade winds limits upwelling of cold nutrient-rich deep water, and its economic effect on local fishing for an international market can be serious. Developing countries that depend on their own agriculture and fishing, particularly those bordering the Pacific Ocean, are usually most affected by El Niño conditions. In this phase of the Oscillation, the pool of warm water in the Pacific near South America is often at its warmest in late December. The 2023 El Niño also disrupted weather patterns globally, with drought reducing maize production by up to 70% in some of Zimbabwe, Zambia and Malawi. The reduced harvests forced countries to declare states of disaster and appeal for international assistance to prevent widespread hunger. It also brought excessive rainfall to East Africa, causing flooding that destroyed crops and infrastructure in areas still recovering from consecutive years of drought.
== Nomenclature == Metastable isomers of a particular isotope are usually designated with an "m". This designation is placed after the mass number of the atom. For example, cobalt-58m1, or 58m127Co, is an isomer of cobalt-58. Here, 27 is the atomic number of cobalt, 58 is the total number of nucleons (meaning it has 31 neutrons), "m" means it is an isomer, and "m1" means it is the first (lowest above the ground state) metastable isomer. For isotopes with more than one metastable isomer, "indices" are placed after the designation, and the labeling becomes m1, m2, m3, and so on. Increasing indices, m1, m2, etc., correlate with increasing levels of excitation energy stored in each of the isomeric states (e.g., hafnium-178m2, or 178m272Hf). The index may be omitted if only one isomer is relevant in-context. For fission isomers, use "f" rather than "m".
=== Health === In a February 2026 livestream, part of an interview with The New York Times, Peters listed substances that were part of his daily routine, including testosterone, Accutane, retatrutide, and nebivolol. He began taking testosterone shots at 14. He also told The New York Times that he suspects he is sterile after years of injecting himself with testosterone and alluded to not necessarily enjoying the act of sex. Declaring himself infertile in the past due to testosterone injections, Peters explained: "So it's just like a negative feedback loop when you're not needing to produce testosterone anymore because your body realizes, okay, we're getting it from an outside source." Peters has stated that he is on the autism spectrum, although he has not been professionally diagnosed. He shared in a June 29, 2026, tweet that he used to stalk strangers so he could study neurotypical human behavior:
C6H12O6 → 2 CH3CHOHCOOH It occurs in the muscles of animals when they need energy faster than the blood can supply oxygen. (In mammals, lactate can be transformed by the liver back into glucose using the Cori cycle.) It also occurs in some kinds of bacteria (such as lactobacilli) and some fungi. It is the type of bacteria that convert lactose into lactic acid in yogurt, giving it its sour taste. These lactic acid bacteria can carry out either homolactic fermentation, where the end-product is mostly lactic acid, or heterolactic fermentation, where some lactate is further metabolized to ethanol and carbon dioxide (via the phosphoketolase pathway), acetate, or other metabolic products, e.g.:
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.